| DC9360 |
Buparvaquone |
Buparvaquone(Butalex) is a hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone; it is a promising compound for the therapy and prophylaxis of all forms of theileriosis. |
|
| DCAPI1497 |
Cancidas
Featured
|
Caspofungin is a semi-synthetic analogue of pneumocandin B0 with improved water solubility, a significant limitation in the development of the echinocandin class as pharmaceuticals. Caspofungin acts by inhibition of the synthesis of β (1,3)-D-glucan, an e |
|
| DCAPI1024 |
Cefditoren pivoxil |
Cefditoren pivoxil |
|
| DCAPI1021 |
Cidofovir(Vistide)
Featured
|
Cidofovir(Vistide) |
|
| DC8937 |
Clarithromycin |
Clarithromycin is a macrolide antibiotic and a CYP3A4 inhibitor. |
|
| DC11061 |
ClpP inhibitor M21 |
ClpP inhibitor M21 is a noncompetitive inhibitor of ClpP with IC50 of 41.42 uM, inhibits ClpP cleavage of SUc-LY-AMC substrate in a peptidase assay. |
|
| DC7761 |
Brincidofovir (CMX-001)
Featured
|
CMX001 (Brincidofovir; HDP-CDV) was developed as an orally active, lipophilic form of cidofovir (CDV); has enhanced activity in vitro and in vivo compared to CDV against certain herpesviruses, adenoviruses and orthopoxviruses.IC50 Value: 5.5 nM (EC50, in PDA at 7 dpi) [3]Target: anti-CMVCMX001 is currently in Phase II clinical studies for development as a therapeutic agent for human CMV, adenovirus and BK virus infections, as well as, for adverse events following smallpox vaccinations.in vitro: In PDA at 7 dpi, the CMX001 50% effective concentration (EC50) was 5.55 nM, the 50% cytotoxic concentration (CC50) was 184.6 nM, and the 50% selectivity index (SI50) was 33.3. The EC90 was 19.7 nM, the CC90 was 5,054 nM, and the SI90 was 256.1. In COS-7 cells, JCV replication was faster and the EC50 and EC90 were 18- and 37-fold higher than those in PDA, i.e., 0.1 μM and 0.74 μM (CC50, 0.67 μM; SI50, 6.7; CC90, 12.2 μM; SI90, 16.5) at 5 dpi [3].in vivo: CMX001 and CDV are equally efficacious at protecting mice from mortality following high ectromelia virus doses (10,000 x LD(50)) introduced by the intra-nasal route or small particle aerosol. Using CMX001 at a 10mg/kg dose followed by 2.5mg/kg doses every other-day for 14 days provided solid protection against mortality and weight loss following an intra-nasal challenge of (100-200) x LD(50) of ectromelia virus [1]. When CMX001 was administered orally to mice infected with HSV-1, mortality was reduced significantly (p≤0.001) with all three dose levels when treatments were initiated 24 h post viral inoculation. When treatments were started 48 h post viral inoculation, 5 and 2.5 mg/kg significantly reduced mortality (p≤ 0.001). If treatments were delayed until 72 h post viral inoculation, CMX001 did not reduce mortality or increase the mean day to death. When mice were infected intranasally with HSV-1 and treatments initiated 24 h post viral inoculation using CMX001 at 5 mg/kg or ACV at 100 mg/kg, virus replication in target organs was reduced by both CMX001 and ACV when compared to vehicle treated mice [2]. Toxicity: Diarrhea was the most common adverse event in patients receiving CMX001 at doses of 200 mg weekly or higher and was dose-limiting at 200 mg twice weekly. Myelosuppression and nephrotoxicity were not observed [4]. |
|
| DC11081 |
Coblopasvir |
Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection.. |
|
| DC10933 |
Compound 3-110-22 |
Compound 3-110-22 is a small molecule that inhibits dengue virus (DENV) by binding to its envelope protein E. |
|
| DC11214 |
Cyclophilin inhibitor C31 |
Cyclophilin inhibitor C31 (SMCypI C31) is a small-molecule cyclophilin (CypA) inhibitor (SMCypI) with PPIase inhibition IC50 of 0.1 uM, displays anti-HCV activity (HCV Gt1b replicon EC50=0.4 uM) and disrupts the CypA-NS5A interaction. |
|
| DC11232 |
D715-2441 |
D715-2441 (D 715-2441) is a novel antiviral compound that interferes with the conserved cap-binding domain of the PB2 protein, exhibits potent antiviral activity against influenza A viruses (IAVs) with IC50 of 1.7-4.4 uM. |
|
| DC7394 |
Daclatasvir dihydrochloride (BMS-790052)
Featured
|
Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. |
|
| DCAPI1493 |
Dalbavacin
Featured
|
Dalbavancin, a semisynthetic lipoglycopeptide being developed for the treatment of skin and skin structure infections (SSSIs), has a half-life of 5 to 7 days in humans and offers promise for a convenient weekly dosing regimen. |
|
| DC8238 |
Danoprevir
Featured
|
Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. |
|
| DC8908 |
Darunavir ethanolate
Featured
|
Darunavir ethanolate is an HIV protease inhibitor,showed potent activity against COVID-19(SARS-COV-2). |
|
| DC7764 |
Delamanid (OPC-67683)
Featured
|
Delamanid (OPC-67683) is an experimental drug for the treatment of multi-drug-resistant tuberculosis. |
|
| DC11352 |
Delavirdine (mesylate) |
Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that selectively inhibits HIV-1 reverse transcriptase over DNA polymerase α and δ in vitro (IC50s = 0.26, 440, and >550 μM, respectively). |
|
| DC8897 |
Delavirdine |
Delavirdine(U 90152) is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI). |
|
| DC10612 |
Delpazolid (LCB01-0371)
Featured
|
Delpazolid (LCB01-0371) is a new oxazolidinone with cyclic amidrazone. |
|
| DC7273 |
Dolutegravir
Featured
|
Dolutegravir (DTG, GSK1349572) is an integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. |
|
| DC10250 |
Dolutegravir Sodium
Featured
|
Dolutegravir is a HIV integrase inhibitor with IC50 of 2.7 nM. |
|
| DC9308 |
Doravirine (MK-1439)
Featured
|
Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor. |
|
| DC9949 |
DprE1-IN-2
Featured
|
DprE1-IN-2 is a potent DprE1 inhibitor. |
|
| DC11409 |
DSM265
Featured
|
DSM265 is a PfDHODH inhibitor with an IC50 of 8.9 nM. DSM265 can also inhibit the growth of P. falciparum 3D7 parasites with an EC50 of 4.3 nM. |
|
| DCAPI1479 |
Efavirenz |
Efavirenz is a nonnucleoside HIV-1 reverse transcriptase (RT) inhibitor which selectively inhibits the glucuronidation of 3'-Azido-3'-deoxythymidine β-D-glucuronide, Sodium Salt. Studies suggest that Efavirenz binds to a distinct site of reverse transcrip |
|
| DC10301 |
Emodepside
Featured
|
Emodepside (PF 1022-221) is a cyclooctadepsipeptide with broad-spectrum anthelmintic activity. |
|
| DC5902 |
Emtricitabine
Featured
|
Emtricitabine is a nucleoside analogue which inhibits the reverse nucleoside transcriptase enzyme. Structurally this antiviral agent is similar to Lamivudine. This agent is effective at targeting HIV and HBV viruses since these viruses replicate in a reve |
|
| DC8440 |
Erythromycin Cyclocarbonate
Featured
|
Erythromycin Cyclocarbonate, derivative of Erythromycin, inhibits protein synthesis of bacteria by binding to the 50S ribosome. |
|
| DC4234 |
Etravirine |
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1). |
|
| DCAPI1011 |
Famciclovir (Famvir) |
Famciclovir (Famvir) |
|
